We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.92%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$443M
AUM Growth
-$5.44M
Cap. Flow
-$82.1M
Cap. Flow %
-18.51%
Top 10 Hldgs %
47.3%
Holding
81
New
8
Increased
12
Reduced
20
Closed
11
Avg Time Held
1.7 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$11.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.61M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M
5
UTHR icon
United Therapeutics
UTHR
+$3.81M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.7M
3
GILD icon
Gilead Sciences
GILD
+$12.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.4M
5
BIIB icon
Biogen
BIIB
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Miscellaneous 0.47%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMGN icon
1
Amgen
AMGN
$236B
$32.6M 7.34%
66,746
-78,000
-54% -$17.9M
2018 Q4
13 quarters
PRTA icon
2
Prothena Corp
PRTA
$434M
$23.8M 5.38%
15,000
– –
2021 Q4
1 quarter
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$31.6B
$21.7M 4.9%
38,000
-90,000
-70% -$13.7M
2017 Q3
18 quarters
ITCI icon
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$20.9M 4.72%
50,956
-62,500
-55% -$3.25M
2020 Q1
8 quarters
HRMY icon
5
Harmony Biosciences
HRMY
$2.23B
$20.5M 4.63%
205,474
-30,526
-13% -$1.25M
2021 Q2
3 quarters
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2B
$19.3M 4.35%
+57,000
New +$914K
2022 Q1
0 quarters
NVAX icon
7
Novavax
NVAX
$1.9B
$18.5M 4.18%
+132,500
New +$11.8M
2022 Q1
0 quarters
RCKT icon
8
Rocket Pharmaceuticals
RCKT
$249M
$17.9M 4.03%
63,000
– –
2021 Q3
2 quarters
SUPN icon
9
Supernus Pharmaceuticals
SUPN
$2.28B
$17.5M 3.94%
297,500
– –
2021 Q2
3 quarters
ZLAB icon
10
Zai Lab
ZLAB
$2.65B
$17M 3.82%
78,958
+40,000
+103% +$1.93M
2021 Q2
3 quarters
INSM icon
11
Insmed
INSM
$21.4B
$14.3M 3.22%
40,100
-81,000
-67% -$1.88M
2019 Q1
12 quarters
QURE icon
12
uniQure
QURE
$1.54B
$11.8M 2.66%
155,500
– –
2019 Q2
11 quarters
VERA icon
13
Vera Therapeutics
VERA
$1.99B
$11.6M 2.62%
190,749
+70,214
+58% +$1.51M
2021 Q4
1 quarter
ONC icon
14
BeOne Medicines Ltd
ONC
$41.7B
$11.4M 2.57%
15,700
-4,300
-22% -$914K
2021 Q4
1 quarter
KALV icon
15
DELISTED
KalVista Pharmaceuticals
KALV
$10.8M 2.44%
383,233
– –
2016 Q4
21 quarters
ILMN icon
16
Illumina
ILMN
$39.7B
$10.8M 2.43%
49,344
+10,794
+28% +$3.65M
2021 Q3
2 quarters
HCM icon
17
HUTCHMED
HCM
$2.46B
$10.1M 2.27%
68,000
– –
2021 Q2
3 quarters
GMDA
18
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$9.98M 2.25%
107,000
– –
2021 Q1
4 quarters
BHVN icon
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.29M 2.1%
130,900
-9,000
-6% -$1.12M
2020 Q2
7 quarters
TPTX
20
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$8.68M 1.96%
14,093
-47,648
-77% -$1.6M
2019 Q4
9 quarters
DNLI icon
21
Denali Therapeutics
DNLI
$2.85B
$8.19M 1.85%
38,000
+12,000
+46% +$413K
2021 Q4
1 quarter
AVDL
22
DELISTED
Avadel Pharmaceuticals
AVDL
$7.65M 1.72%
+50,000
New +$344K
2022 Q1
0 quarters
SNY icon
23
Sanofi
SNY
$96.9B
$7.64M 1.72%
+31,500
New +$1.63M
2022 Q1
0 quarters
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.45M 1.68%
183,473
+83,600
+84% +$8.15M
2016 Q4
21 quarters
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$13.8B
$5.92M 1.34%
17,200
-27,000
-61% -$3.92M
2021 Q2
3 quarters
1
2 3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2022 Portfolio in Review

As of Q1 2022, International Biotechnology Trust held 81 positions worth $443M, down 1.2% from $449M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $82.1M in Q1 2022, closing 11 positions and reducing 20 holdings. Its most notable exit was Biogen, an estimated $11.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Utilities.

Against the trend, International Biotechnology Trust opened a new position in Novavax worth $18.5M.

  • International Biotechnology Trust's largest Q1 2022 buy was Novavax: 132,500 shares worth $18.5M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022, an estimated $8.15M increase.
  • International Biotechnology Trust's biggest Q1 2022 reduction was Amgen, cutting an estimated $17.9M.
  • International Biotechnology Trust fully exited Biogen in Q1 2022, selling an estimated $11.4M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $443M portfolio in Q1 2022.
  • International Biotechnology Trust opened 8 new positions and closed 11 in Q1 2022.
  • International Biotechnology Trust's portfolio value fell 1.2% quarter-over-quarter to $443M.

Based on International Biotechnology Trust's 13F filing for Q1 2022, filed 20 May 2022.